Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Dynavax Technologies’ Revenue Breakdown Worldwide from Q2 2020 onwards, split between the United States and Non-US (Rest of the World).
|Region||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
(All figures are in millions, except percentages)
The total revenue has shown an increase of $94.86 million, from $13.41 million in Q2 2020 to $108.27 million in Q3 2021 on a YOY basis. Moreover, for the latest quarter in 2021, 77.92% of the revenue can be traced back to the Non-US.
In Q3 2021, Dynavax recorded an exceptionally high revenue of $23.91 million from the United States. Also, earnings from the Non-US Countries were approximately $84.36 million for Q3 2021.
In the United States, the pharmaceutical industry has formerly been significantly affected by major legislative enterprises, including, for example, the ACA. The ACA, among other things, imposes a significant periodic figure on companies that manufacture or import ingrained traditional medicine products.
There are civil and state anti-kickback laws that enjoin the payment or damage of effects, backhanders, or other remuneration intended to induce the purchase or recommendation of healthcare products and services or award once purchases or recommendations.
Revenue from the United States has a contribution of 22.08% to the company’s total revenue as of Q3 2021. This region showed revenue of $23.91 million in Q3 2021 with an increase of 106.12% from Q3 2020 on a YOY basis and 74.65% from Q2 2021 on a quarterly basis. Dynavax Technology has been growing rapidly in recent periods and, as a result, has a relatively short history of operating its business at its current scale.
Non-US (Rest of the world)
Outside the United States, the company and its branches deal in products that are contingent upon carrying marketing authorization from the applicable nonsupervisory authorities. The conditions governing marketing authorization, pricing, and payment vary extensively from country to country and region to region.
The majority of the total revenue of the company is generated by the Non-United States with a contribution of 77.92% as of Q3 2021. They had shown an increase of $82.54 million and $45.28 million as compared to Q3 2020 and Q2 2021 respectively. The increase in compensation and related personnel costs was due to a higher headcount resulting from the conversion of the external sales force to our employees effective April 1, 2019, offset by the decrease in business travel due to COVID-19 travel restrictions.
Impact of Covid-19
The extent of the impact of the COVID-19 epidemic on their capability to generate sales and revenues, nonsupervisory sweats, commercial development objects, and the value of and request for the common stock will depend on coming developments that are largely uncertain and can not be predicted with confidence at this time. Because of the below and other factors, results of operations may vary mainly from time to time and from quarter to quarter and, as a result, they believe that period-to-period comparisons of their operating results may not be meaningful and shouldn’t be reckoned upon as being reflective of the unborn performance.
About the company
Dynavax Technologies is a biopharmaceutical company discovering and developing new products to help and treat contagious diseases. Dynavax Technologies Corporation (Nasdaq DVAX) is a completely- integrated biopharmaceutical company concentrated on using the power of the body’s ingrain and adaptive vulnerable responses through Risk-suchlike Receptor (TLR) stimulation. Dynavax develops and commercializes new vaccines.
The Company has worldwide commercial rights to HEPLISAV-B (their first product) and markets it in the United States. It developed CpG 1018 to give an increased vaccine vulnerable response, as demonstrated in HEPLISAV-B. They’re expanding the use of CpG 1018 to support the development and implicit large-scale manufacturing of fresh vaccines through collaborations with multiple vaccine companies and academic groups and in their vaccine development programs.
Did you like Dynavax Technologies’ Revenue Breakdown Worldwide statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.